Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...“The art and challenge of developing nanoparticles is to combine lipids with different physical characteristics in a way that stabilises the RNA as effectively as possible,” said Mike Watson, a former head...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...“It’s the biggest vaccine programme in history and the logistics are enormous,” said Dr Nigel Watson, chief executive of the Wessex Local Medical Committees....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Meanwhile, the French drugmaker Sanofi recently joined forces with Verily Life Sciences to work on devices and patient support for diabetics, and Pfizer is working with IBM Watson as part of its work on...
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...small generics drugmaker known as Watson to one of the world’s biggest pharma groups....
...Allergan (formerly known as Actavis and before that as Watson) describes itself as pioneering a new model in the drug sector....
...While multinationals like Pfizer have begun to introduce their own “branded generic” lines in a bid to compete, many have dismantled domestic production altogether, preferring to import or subcontract production...
...Some investors even say such a deal could pave the way for Mr Saunders to eventually replace Ian Read as chief executive of Pfizer....
...In 2012 it was Watson Pharmaceuticals, a generic drugmaker with a market capitalisation of $8bn — a fraction of the $113bn it is worth today....
...From Alexander Fleming’s discovery of penicillin to the modelling of DNA by Francis Crick and James Watson, Britain’s scientists and pharmaceutical companies have been at the forefront of the life sciences...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Calpers, the largest US pension fund, and Towers Watson, the consultancy that counts some of the world’s biggest institutional investors among its clients, declined to comment on the issue....
...● Watson is to rebrand next year as Actavis, the name of the Swiss-based company it bought for €4.3bn....
...Jeff Kindler of Pfizer resigned in 2010 as chief executive of the US drug company, saying he needed to “recharge [his] batteries”....
...That did not include Pfizer’s $11.8bn sale of its infant nutrition business to Nestlé....
...Just two generic companies, India’s Ranbaxy and Watson Pharma, which has agreed a distribution deal with Pfizer, are allowed to compete with Pfizer under a six-month exclusivity agreement....
...Nestlé paid a hefty $12bn for Pfizer’s infant nutrition business to gain emerging market share, and Watson agreed a €4.5bn takeover of Actavis to create one of the world’s largest generic drugs group....
...But Pfizer is expected to generate about $500m in revenues and maintain a 40 per cent market share of Lipitor during the next six months, when Watson Pharmaceuticals and Ranbaxy will be its only competition...
...Ranbaxy Laboratories, an Indian drug company, and Watson Pharmaceuticals are the only companies with rights to sell generic Lipitor for the next six months, at which point other companies can enter the market...
...The company also plans to distribute an “authorised” generic version through Watson Pharmaceuticals and has considered trying to sell an over-the-counter version of the drug....
...The other company that will be allowed to launch the generic version Thursday is Pfizer’s generic partner, Watson Pharmaceuticals, which has FDA-approval to market the drug in the US and could easily take...
International Edition